oderate growth of the market is due to the increasing awareness among people about the importance of vaccination against influenza vaccines, and the approval of new influenza vaccines vaccines. The universal immunization recommendation by the Advisory Committee on Immunization Practices (ACIP) and several government awareness vaccination programs would help to increase the vaccination coverage for influenza vaccines. The upcoming influenza vaccines vaccines include seasonal vaccines such as FluBlok and MEDI-3250, pandemic and pre-pandemic (mainly H5N1) vaccines such as Flu (Pre) Pandemic Vaccine, H5N1 pandemic influenza vaccines vaccine and Vepacel, and universal influenza vaccines vaccines such as BVX-M001, MVA-NP+M1, Flu-v and others. The influenza vaccines vaccines market is also set to witness the launch of quadrivalent vaccines such as Fluzone QIV, and adjuvant vaccines such as JVRS-100 with Fluzone and IC31 Seasonal influenza vaccines Vaccine. The pipeline also includes vaccines with different routes of administration, such as oral vaccine (Avian influenza vaccines (H5N1) Oral Vaccine), nasal vaccine (influenza vaccines Intranasal Vaccine), vaccine in the form of nasal dry powder (GelVac), and vaccine patch (Pandemic influenza vaccines Vaccine Patch).
The report provides information on the key drivers and challenges of the influenza vaccines market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) influenza vaccines market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, type of vaccines being developed and emerging trends by seven key markets. Pipeline candidates fall under major classes such as conjugate vaccine, combinational vaccine, polysachharide vaccines and others.
- Analysis of the current and future competition in the seven key countries influenza vacciPage: 1 2 3 4 5 6 7 8 9 Related biology technology :1
. GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season2
. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic3
. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season4
. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate5
. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial6
. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program7
. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production8
. Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy9
. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza10
. A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks11
. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza